Jay T. Bishoff named regional director of urology at Northwell Health

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

Jay T. Bishoff was named director of urology for Northwell Health’s Central Region, with oversight of urology sites in Nassau County and parts of eastern Queens. 

He also is a professor of urology at the Donald and Barbara Zucker School of Medicine at Hofstra/Northwell. His appointment is effective Aug. 2.

Based at Northwell’s The Smith Institute of Urology, with affiliations at North Shore University Hospital and Long Island Jewish Medical Center, Bishoff treats urological cancer patients using robotic and laparoscopic techniques. 

He is an expert in developing programs for quality improvement to increase better health outcomes. His areas of research and interest include cancer of the prostate, kidney, adrenal gland and testis.

Prior to joining Northwell, Bishoff was director of Intermountain Urological Institute at Intermountain Health Care in Salt Lake City, where he also held other clinical leadership positions over a 15-year span. 

Earlier, Bishoff was a U.S. Air Force surgeon, serving from 1998 to 2006, including during Operation Iraqi Freedom, treating patients at Balad, Iraq. He is also the author of Boots of War: Unforgettable Experiences from a Front Line Surgeon During Operation Iraqi Freedom.

Table of Contents

YOU MAY BE INTERESTED IN

When our hematological malignancy testing pilot project began in Eldoret, Kenya, there seemed to be a mismatch in relation to progress in healthcare. The region, like much of sub-Saharan Africa, had been focusing on combatting infectious diseases such as HIV and malaria—which was much-needed—yet cancer care was under-resourced. 
Artificial intelligence is rapidly transforming biomedical research and healthcare. Large language models, foundation models, and AI agents are increasingly being deployed to assist with data interpretation, literature review, clinical decision support, and translational research. 
In modern oncology, important insights from clinical trials often emerge years after initial publication. As new therapies extend survival and transition more patients into long-term remissions, clinicians and researchers are increasingly looking beyond initial response rates to understand durability, long-term safety, and even the possibility of a cure. 

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login